Biovica announces that the company’s quality system is updated in accordance with  ISO 13485:2016.

Uppsala, Sweden, February 4, 2019. Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, announced today that the company has certified their Quality System according to the ISO13485:2016 standard for the development, manufacturing and sale of DiviTum® at the yearly surveillance audit with Biovica’s notified body.  

2019-02-16T00:09:50+00:00 February 4th, 2019 07:57|News|
Read More

Biovica meddelar att bolagets kvalitetssystem är uppdaterat i enlighet med ISO 13485:2016

Uppsala, den 4 februari 2019. Biovica, utvecklar och kommersialiserar blodbaserade biomarkörer i syfte att utvärdera effekten av cancerbehandlingar, meddelar idag att bolaget vid den årliga uppföljningsrevisionen (surveillance audit) av sitt anmälda organ (notified body) även uppgraderat sitt kvalitetssystem i enlighet med ISO 13485:2016 för utveckling, tillverkning och försäljning av bolagets DiviTum®.

2019-02-16T00:09:49+00:00 February 4th, 2019 07:57|News|
Read More
In the United States and Japan DiviTum® is currently available for research purposes only.
All information, without limitation, on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not constitute medical or other professional advice. DiviTum® is CE-labelled, registered by the Swedish Medical Products Agency.

Copyright 2017 Biovica | All Rights Reserved